Ozempic vs Mounjaro vs Wegovy: Which GLP-1 Is Right for You?

Ozempic, Mounjaro, and Wegovy are the three most prescribed GLP-1 receptor agonists for weight loss and metabolic health. They share a similar mechanism but differ in active ingredients, dosing, clinical results, and cost. Choosing between them depends on your goals, your insurance, and how your body responds.

This guide breaks down the clinical data so you can have an informed conversation with your doctor about which medication fits your situation.

What Are These Medications?

All three belong to a drug class called GLP-1 receptor agonists (or "GLP-1s"). They mimic a gut hormone called glucagon-like peptide-1 that regulates appetite, blood sugar, and gastric emptying. Here is the quick breakdown:

Ozempic was approved in 2017 for type 2 diabetes. Doctors began prescribing it off-label for weight loss after clinical trials showed significant body weight reduction. It contains semaglutide, a synthetic version of human GLP-1 with a half-life of about 7 days.

Wegovy is the same molecule as Ozempic (semaglutide) at a higher dose. Novo Nordisk received FDA approval for Wegovy as a dedicated weight management drug in 2021. The key difference is dose: Wegovy tops out at 2.4 mg weekly vs. Ozempic's 2 mg.

Mounjaro is tirzepatide, made by Eli Lilly. It targets two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-agonist approach produced the strongest weight loss results in clinical trials. Mounjaro received FDA approval for type 2 diabetes in 2022, and its weight management version (Zepbound) was approved in 2023.

How They Work: Mechanism of Action

GLP-1 receptor agonists work through several pathways at once:

• Appetite suppression: They act on hypothalamic neurons that control hunger and satiety, reducing calorie intake by 20-35% in most users.
• Slowed gastric emptying: Food stays in the stomach longer, which increases fullness after smaller meals.
• Improved insulin sensitivity: They enhance insulin secretion when blood sugar is elevated and suppress glucagon release.
• Reduced food reward signaling: Brain imaging studies show decreased activation in reward centers when viewing food.

Where Mounjaro Differs

Mounjaro's dual GLP-1/GIP mechanism adds a second pathway. GIP receptors are found in fat tissue, the brain, and the pancreas. Activating both receptors appears to produce stronger appetite suppression and greater improvements in insulin sensitivity compared to GLP-1 alone (Frias et al., The Lancet, 2021).

Weight Loss Results: Head-to-Head Data

Clinical trial data provides the clearest comparison. These numbers come from phase 3 trials, each running 68-72 weeks with thousands of participants.

Key takeaways from the trial data:

• Mounjaro at 15 mg produced the greatest average weight loss at 22.5% of body weight, about 52 lbs for someone starting at 230 lbs (Jastreboff et al., NEJM, 2022).
• Wegovy (semaglutide 2.4 mg) averaged 14.9%, roughly 34 lbs from the same starting weight (Wilding et al., NEJM, 2021).
• Ozempic at its approved diabetes dose (up to 2 mg) produces less weight loss because the dose is lower than Wegovy.
• Mounjaro's lowest dose (5 mg) matched Wegovy's highest dose in terms of percentage body weight lost.

The SURMOUNT-5 trial (2024) was the first direct head-to-head comparison. Tirzepatide 15 mg achieved 20.2% weight loss vs. semaglutide 2.4 mg at 13.7% over 72 weeks, confirming Mounjaro's advantage in a randomized setting (Aronne et al., NEJM, 2024).

Dosing Schedules

All three medications use a slow-titration approach: you start low and increase the dose every 4 weeks to minimize side effects. Rushing the titration is the most common mistake and the biggest cause of severe nausea.

Side Effects Compared

GLP-1 medications share a similar side effect profile because they work through related pathways. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are worst during the first 4-8 weeks and during dose increases.

Wegovy shows higher side effect rates partly because the dose is higher (2.4 mg vs. Ozempic's 1-2 mg of the same molecule). Mounjaro's GI side effects were generally comparable to or lower than Wegovy at equivalent weight loss levels.

Serious Side Effects to Watch For

Rare but serious adverse events are similar across all three:

• Pancreatitis: Reported in less than 1% of users. Stop the medication and seek emergency care if you have severe, persistent abdominal pain radiating to the back.
• Gallbladder issues: Rapid weight loss increases gallstone risk regardless of medication. Stay hydrated and report right upper quadrant pain.
• Thyroid C-cell tumors: Seen in rodent studies at high doses. All three carry a boxed warning. Not confirmed in humans, but these medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN 2.
• Hypoglycemia: Rare when used alone, but risk increases if combined with insulin or sulfonylureas.

For a deeper look at managing GI symptoms, read our GLP-1 Side Effects Playbook and the guides on nausea and reflux and constipation management.

Cost and Insurance Coverage

Cost is often the deciding factor. GLP-1 medications are expensive, and coverage varies dramatically by insurer, plan tier, and diagnosis.

Insurance Coverage Tips

• Type 2 diabetes diagnosis: If you have T2D, all three are usually covered under pharmacy benefits. Ozempic and Mounjaro are most commonly formulary drugs for diabetes.
• Weight management only: Coverage for Wegovy (and Zepbound, Mounjaro's weight-loss version) is growing but still inconsistent. Many employers and Medicare plans do not cover anti-obesity medications.
• Prior authorization: Most insurers require documented BMI of 30+ (or 27+ with a comorbidity), plus evidence that diet and exercise alone were insufficient.
• Manufacturer programs: Both Novo Nordisk and Eli Lilly offer savings cards that can drop copays to $25/month for commercially insured patients. Check their websites directly.
• Step therapy: Some plans require you to try a lower-cost option (like Ozempic) before approving Wegovy or Mounjaro.

Which One Is Right for You?

There is no universal "best" GLP-1. The right choice depends on your diagnosis, insurance coverage, weight loss goals, and how your body tolerates the medication. Here is a simplified decision framework:

Consider Ozempic If...

• You have type 2 diabetes and want blood sugar control with moderate weight loss
• Your insurance covers Ozempic but not Wegovy
• You prefer a medication with 7+ years of post-market safety data
• You want to start with a lower-dose option and see how you respond

Consider Wegovy If...

• Weight loss is your primary goal (not just blood sugar management)
• You have a BMI of 30+ or 27+ with a weight-related comorbidity
• Your insurance covers anti-obesity medications
• You want the FDA-approved semaglutide dose for weight management

Consider Mounjaro If...

• You want the highest potential weight loss based on clinical trial data
• You have type 2 diabetes with significant insulin resistance
• You did not respond well to semaglutide (Ozempic/Wegovy)
• You are comfortable with a newer drug that has less long-term safety data

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2 mg/week. Wegovy is approved for weight management at 2.4 mg/week. The higher Wegovy dose produces more weight loss, but the side effects can also be more pronounced. If your doctor prescribes Ozempic off-label for weight loss, you are getting the same molecule at a slightly lower maximum dose.

Is Mounjaro better than Ozempic for weight loss?

In clinical trials, yes. Mounjaro (tirzepatide) at its highest dose produced 22.5% average body weight loss vs. about 15% for semaglutide 2.4 mg. The SURMOUNT-5 head-to-head trial confirmed tirzepatide's advantage (Aronne et al.,NEJM, 2024). But "better" also depends on cost, insurance coverage, side effect tolerance, and your individual response. Some people do better on semaglutide.

How much do Ozempic, Mounjaro, and Wegovy cost without insurance?

Rough monthly estimates: Ozempic $900-$1,100, Mounjaro $1,000-$1,200, Wegovy $1,300-$1,500. Manufacturer savings programs can lower this significantly. Prices change frequently, so check GoodRx or your pharmacy for current rates.

Can you switch from Ozempic to Mounjaro?

Yes. Switching is common and does not require a washout period. Your doctor will start you at a lower Mounjaro dose (typically 2.5 mg) and titrate up, even if you were on a high dose of Ozempic. Expect some adjustment as your body adapts to the new receptor profile.

Do you regain weight after stopping Ozempic or Mounjaro?

Most people regain weight after discontinuation. The STEP 1 extension trial showed about two-thirds of weight loss was regained within a year of stopping semaglutide (Wilding et al., Diabetes, Obesity and Metabolism, 2022). This is why many doctors view GLP-1 medications as long-term therapy for chronic obesity, similar to blood pressure medication for hypertension. Building strong exercise and nutrition habits while on the medication gives you the best chance of maintaining results.

The Bottom Line

Ozempic, Wegovy, and Mounjaro are all effective tools for weight loss and metabolic health. Mounjaro shows the strongest weight loss numbers in trials. Wegovy is the go-to semaglutide option for dedicated weight management. Ozempic remains the most accessible for people with type 2 diabetes.

The medication is only one part of the equation. Diet, exercise, sleep, and stress management all determine your long-term results. If you are considering a GLP-1, start by talking with your doctor about your goals, your insurance options, and which medication makes sense for your specific health profile.

For week-by-week guidance on what to expect after starting, read our GLP-1 Week-by-Week Timeline.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link
2. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. Link
3. Sorli C, Harber S, Engel SS, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260. Link
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Link
5. Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;392(18):1743-1754. Link
6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. Link
7. U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. Revised 2025. Link
8. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. Revised 2024. Link